Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 501–600 of 1,002
Pharmaceutical R&D Performance by Firm Size: Approval Success Rates and Economic Returns
DiMasi, J. A. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318269198f · Cited by 36
Zebrafish small molecule screens: Taking the phenotypic plunge
Williams, C. H., & Hong, C. C. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.001 · Cited by 41
“recent decades, with the costs of developing a new drug seeming to grow exponentially, a trend termed “Eroom's Law”, to contrast with the Moore's Law describing exponential growth in computing power [51].”
BackgroundOn the role of forces governing particulate interactions in pharmaceutical systems: A review
Sarkar, S., Mukherjee, R., & Chaudhuri, B. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.003 · Cited by 35
A novel tissue-engineered 3D tumor model for anti-cancer drug discovery
Li, W., Hu, X., Yang, S., Wang, S., Zhang, C., Wang, H., Cheng, Y. Y., Wang, Y., Liu, T., & Song, K. (2018) · Biofabrication · doi:10.1088/1758-5090/aae270 · Cited by 39
Accelerated drug discovery by rapid candidate drug identification
Bergström, F., & Lindmark, B. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.026 · Cited by 37
Guidelines for Translational Research in Heart Failure
Lara‐Pezzi, E., Menasché, P., Trouvin, J., Badimón, L., Ioannidis, J. P. A., Wu, J. C., Hill, J. A., Koch, W. J., Felice, A. F. D., Waele, P. D., et al. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-015-9606-8 · Cited by 35
“As discussed above, cardiac toxicity is the leading cause of drug attrition during pharmaceutical development and is a primary cause of drug withdrawal after market release, accounting for 42 % of all drugs withdrawn due to safety concerns between 1994 and 2006 [112, 113].”
BackgroundZineh, I., & Woodcock, J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.32 · Cited by 34
Bajaj, P., Harris, J. F., Huang, J., Nath, P., & Iyer, R. S. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00480 · Cited by 37
An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation
Jie, M., Lin, H., He, Z., Liu, H., Li, H., & Lin, J. (2017) · Science China Chemistry · doi:10.1007/s11426-017-9167-0 · Cited by 34
Park, J. H., Grijalva, S. I., Jung, D., Li, S., Junek, G. V., Chi, T., Cho, H. C., & Wang, H. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111626 · Cited by 35
Kothamachu, V. B., Zaini, S., & Muffatto, F. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630320931794 · Cited by 39
“25(5) 411 –426 © 2020 Society for Laboratory Automation and Screening DOI: 10.”
BackgroundDrug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Shakkour, Z., Issa, H., Ismail, H., Ashekyan, O., Habashy, K. J., Nasrallah, L., Jourdi, H., Hamade, E., Mondello, S., Sabra, M., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200812221022 · Cited by 34
Kropiwnicki, E., Evangelista, J. E., Stein, D. J., Clarke, D. J. B., Lachmann, A., Kuleshov, M. V., Jeon, M., Jagodnik, K. M., & Ma’ayan, A. (2021) · Database · doi:10.1093/database/baab017 · Cited by 37
“Currently, drug discovery efforts suffer from high attrition rates, long research and development timelines, and high financial costs (1, 2).”
BackgroundSSGraphCPI: A Novel Model for Predicting Compound-Protein Interactions Based on Deep Learning
Wang, X., Liu, J., Zhang, C., & Wang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073780 · Cited by 35
An Orchestration Framework for Digital Innovation: Lessons From the Healthcare Industry
Satwekar, A., Volpentesta, T., Spagnoletti, P., & Rossi, M. (2022) · IEEE Transactions on Engineering Management · doi:10.1109/tem.2022.3167259 · Cited by 36
“Specifically for biopharmaceutical companies, there has been a decrease in research and development productivity, leading to increased costs within the past few decades [11], [12].”
BackgroundTranslational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 35
“This is, in part, a reflection of Eroom’s law [61] a recently proposed inversion of the well-known law in computing,”
BackgroundHolmes, A. M., Charlton, A., Derby, B., Ewart, L. C., Scott, A., & Shu, W. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7bbd · Cited by 40
Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands
Moors, E. H. M., Kukk, P., Boon, W., Schellen, F., & Negro, S. O. (2017) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2017.11.011 · Cited by 34
Soft drugs: design principles, success stories, and future perspectives
Buchwald, P. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1777280 · Cited by 34
Exaptation, serendipity and aging
Andriani, P. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.01.001 · Cited by 33
Nene, L. N. Z., Flepisi, B. T., Brand, S. J., Basson, C., & Balmith, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.05.012 · Cited by 42
Gerüstdiversitätsbasierte Synthese und ihre Anwendung bei der Sonden‐ und Wirkstoffsuche
García-Castro, M., Zimmermann, S., Sankar, M. G., & Kumar, K. (2016) · Angewandte Chemie · doi:10.1002/ange.201508818 · Cited by 33
Comte, B., Baumbach, J., Benis, A., Basílio, J., Debeljak, N., Flobak, Å., Franken, C., Harel, N., HeFeng, F. Q., Kuiper, M. T. R., et al. (2020) · Network and Systems Medicine · doi:10.1089/nsm.2020.0004 · Cited by 33
“Since the 1950s, the efficacy of translating biomedical research into successful drug discovery is on a constant decline.(4,5) Two key factors have contributed to this innovation roadblock.”
BackgroundGarcía‐Viñuales, S., Sciacca, M. F. M., Lanza, V., Santoro, A. M., Grasso, G., Tundo, G. R., Sbardella, D., Coletta, M., Grasso, G., Rosa, C. L., et al. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105072 · Cited by 35
Jung, D., Junek, G. V., Park, J.-S., Kumashi, S., Wang, A. Y., Li, S., Grijalva, S. I., Fernandez, N., Cho, H. C., & Wang, H. (2021) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2021.3085571 · Cited by 34
Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders
Truong, T. T. T., Panizzutti, B., Kim, J. H., & Walder, K. R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071464 · Cited by 36
“The whole process usually takes approximately 13–15 years from initial discovery to final regulatory approval, and costs USD 2–3 billion [7].”
BackgroundOpen innovation in early drug discovery: roadmaps and roadblocks
Reichman, M., & Simpson, P. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.008 · Cited by 34
Control of the Morphology of Lipid Layers by Substrate Surface Chemistry
Granqvist, N., Yliperttula, M. L., Välimäki, S., Pulkkinen, P. M. S., Tenhu, H. J., & Viitala, T. (2014) · Langmuir · doi:10.1021/la4046622 · Cited by 37
Expanding roles for academic entrepreneurship in drug discovery
Kinch, M. S., Horn, C., Kraft, Z., & Schwartz, T. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.004 · Cited by 32
Ahmad, B., Ouahada, K., & Hamam, H. (2026) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.12.033 · Cited by 38
TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Song, Y., & Buchwald, P. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223115628 · Cited by 34
“As drug research and discovery are facing increasing challenges and difficulties in identifying innovative new therapeutics [1, 2], small-molecule modulation of protein-protein interactions (PPIs) has emerged as a possible alternative approach that might be challenging, but could offer particularly valuable solutions.”
BackgroundUsing Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
Kirouac, D. C., & Onsum, M. D. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.38 · Cited by 35
“CPT: Pharmacometrics & Systems Pharmacology (2013) 2 , e71; doi:10.1038/psp.2013.38; published online 4 September 2013 are generally sufficient for purposes in which they were developed—defining dosing regimens for monotherapies, based on existing clinical data.”
BackgroundInfluentialBariotakis, M., Georgescu, L., Laina, D., Oikonomou, I., Ntagounakis, G., Koufaki, M.-I., Souma, M., Choreftakis, M., Zormpa, O. G., Smýkal, P., et al. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.133681 · Cited by 33
PaccMannRL: Designing Anticancer Drugs From Transcriptomic Data via Reinforcement Learning
Born, J., Manica, M., Oskooei, A., Cadow, J., & Martínez, M. R. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-45257-5_18 · Cited by 38
“01%), with an estimated 10-15 years until market release and costs that range between one [1] to three billion dollars per drug [2].”
BackgroundZulfiqar, Z., Shah, F. A., Shafique, S., Alattar, A., Ali, T., Alvi, A. M., Rashid, S., & Li, S. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s284471 · Cited by 33
RetractedCrisis in Infectious Diseases: 2 Decades Later
Casadevall, A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix067 · Cited by 32
AACR Cancer Progress Report 2012
Cantley, L. C., Dalton, W. S., DuBois, R. N., Finn, O. J., Futreal, P. A., Golub, T. R., Hait, W. N., Lozano, G., Maris, J. M., Nelson, W. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2891 · Cited by 36
Fabrication of organ-on-a-chip using microfluidics
Ying-Jin, S., Yuste, I., González‐Burgos, E., & Serrano, D. R. (2025) · Bioprinting · doi:10.1016/j.bprint.2025.e00394 · Cited by 36
Mafu, S., Karunanithi, P. S., Palazzo, T. A., Harrod, B. L., Rodriguez, S. M., Mollhoff, I. N., O’Brien, T. E., Shen, T., Fiehn, O., Tantillo, D. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612901114 · Cited by 31
“Exploring this space has the potential to contribute to devising therapeutic lead compounds in the face of drug discovery over recent decades having fallen short of meeting the demand for new and improved therapies (32).”
BackgroundDiversity of Bioactive Compounds and Their Therapeutic Potential
Altaf, M. M., Khan, M. S., & Ahmad, I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814619-4.00002-1 · Cited by 31
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 35
Kalot, R., Mhanna, R., & Talhouk, R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108156 · Cited by 31
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets
Lago, S. G., & Bahn, S. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00290-4 · Cited by 32
Cell morphology-guided de novo hit design by conditioning GANs on phenotypic image features
Zapata, P. A. M., Méndez‐Lucio, O., Le, T., Beese, C. J., Wichard, J., Rouquié, D., & Clevert, D.-A. (2022) · Digital Discovery · doi:10.1039/d2dd00081d · Cited by 40
Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study
Mol, P. G. M., Arnardottir, A. H., Motola, D., Vrijlandt, P. J. W. S., Duijnhoven, R. G., Haaijer‐Ruskamp, F. M., de Graeff, P. A., Denig, P., & Straus, S. M. J. M. (2013) · Drug Safety · doi:10.1007/s40264-013-0094-y · Cited by 31
Understanding drugs and diseases by systems biology?
Schneider, H.-C., & Klabunde, T. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.031 · Cited by 36
Future directions in phosphodiesterase drug discovery
DeNinno, M. P. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.028 · Cited by 31
Designer bacteria as intratumoural enzyme biofactories
Lehouritis, P., Hogan, G. E., & Tangney, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.012 · Cited by 33
“A decline in R&D efficiency is evident, and it is speculated that it is becoming harder for novelmedicines to reach the clinic, partly because of increasingly demanding regulatory authorities and the extremely high expectations of healthcare standards set by existing treatments [181].”
BackgroundFrom Target Identification to Drug Development in Space: Using the Microgravity Assist
Braddock, M. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666190112150014 · Cited by 36
Exploring new technologies in biomedical research
Benam, K. H., Gilchrist, S., Kleensang, A., Satz, A. B., Willett, C., & Zhang, Q. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.001 · Cited by 35
Nayarisseri, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662019200701164759 · Cited by 34
Key aspects for conception and construction of co-culture models of tumor-stroma interactions
Mason, J. E., & Öhlund, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1150764 · Cited by 32
“However, this approach has some severe limitations; not least the disheartening statistic that the vast majority of therapeutics developed against 2D tumor cell cultures fail to translate to clinic or even animal models (Scannell et al., 2012; Seyhan, 2019).”
BackgroundForward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022
Gu, M., Sun, S., You, Q., & Wang, L. (2023) · Molecules · doi:10.3390/molecules28247941 · Cited by 33
Highly scalable and standardized organ-on-chip platform with TEER for biological barrier modeling
Nguyen, H.-T., Rissanen, S.-L., Peltokangas, M., Laakkonen, T., Kettunen, J., Barthod, L., Sivakumar, R., Palojärvi, A., Junttila, P., Talvitie, J., et al. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2315702 · Cited by 31
Streamlining Change Control Processes in Regulatory Affairs: Best Practices and Case Studies
Challa, S. S. S., Chawda, A. D., Benke, A. P., & Tilala, M. (2024) · Integrated Journal for Research in Arts and Humanities · doi:10.55544/ijrah.4.4.12 · Cited by 39
Khan, A. F., & Iturria‐Medina, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03073-w · Cited by 35
“In general, the ratio of research and development expenses to FDA-approved drugs has been rising exponentially since the middle of the 20 th century [325].”
BackgroundBoyle, C. F., Levin, C., Hatefi, A., Madriz, S., & Santos, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140092 · Cited by 30
“This may not be the case over the next 15–20 years, as there is evidence that innovations in health are becoming harder to find [34].”
BackgroundProcacci, P. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp05519a · Cited by 35
“[2] J.”
BackgroundPark, J.-S., Grijalva, S. I., Aziz, M. K., Chi, T., Li, S., Sayegh, M. N., Wang, A. Y., Cho, H. C., & Wang, H. (2018) · Lab on a Chip · doi:10.1039/c8lc00156a · Cited by 32
A rapid method for post-antibiotic bacterial susceptibility testing
Heller, A. A., & Spence, D. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210534 · Cited by 33
Electronic Health Records for Drug Repurposing: Current Status, Challenges, and Future Directions
Xu, H., Li, J., Jiang, X., & Chen, Q. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1769 · Cited by 30
“billion with the total time to bring it to the market being about 13–15 years).(1) Therefore, drug repurposing (also called drug”
BackgroundExploration of the correlation between GPCRs and drugs based on a learning to rank algorithm
Ru, X., Wang, L., Li, L., Ding, H., Ye, X., & Zou, Q. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103660 · Cited by 32
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Rebelo, R., Polónia, B. R. G., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2021) · Pharmaceuticals · doi:10.3390/ph14030280 · Cited by 34
Zhu, H., Chen, C. Z., Sakamuru, S., Zhao, J., Ngan, D. K., Simeonov, A. M., Hall, M. D., Xia, M., Zheng, W., & Huang, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-86110-8 · Cited by 33
Demarque, D. P., & Espíndola, L. S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.779049 · Cited by 31
Chen, J., Gu, Z., Xu, Y., Deng, M., Lai, L., & Pei, J. (2022) · Protein Science · doi:10.1002/pro.4555 · Cited by 34
Islam, K., Amaya-Ramírez, D., Maigret, B., Devignes, M., Aridhi, S., & Smaïl‐Tabbone, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-30095-z · Cited by 39
“The top-100 predictions are evaluated based on two groups of methods: (1) cross-matching with in-trial drugs for COVID-19 and (2) molecular evaluation based on compound and protein structures.”
Chambers, J. D., Thorat, T., Pyo, J., Chenoweth, M. D., & Neumann, P. J. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0574 · Cited by 30
Sewell, F. R., Chapman, K. L., Couch, J. A., Dempster, M., Heidel, S. M., Loberg, L. I., Maier, C. C., MacLachlan, T. K., Todd, M. D., & van der Laan, J. W. (2017) · mAbs · doi:10.1080/19420862.2017.1324376 · Cited by 30
“There is some recent evidence that R&D productivity has turned a corner and the industry is sustainable again.(20,21) However, attrition, which may be due to lack of efficacy as well as lack of translational safety, is still a huge problem, costing an estimated $1.”
BackgroundSaesen, R., Lejeune, S., Quaglio, G., Lacombe, D., & Huys, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00043 · Cited by 30
Rossinelli, D., Tang, Y., Lykov, K., Alexeev, D., Bernaschi, M., Hadjidoukas, P. E., Bisson, M., Joubert, W. D., Conti, C., Karniadakis, G. E., et al. (2015) · International Conference for High Performance Computing, Networking, Storage and Analysis (SC) · doi:10.1145/2807591.2807677 · Cited by 42
“Fast turnaround times for design are essential for the evolving technologies (3D printing, liquid biopsies, organ-on-a-chip) of microfluidic chips that can assist medical analysis and drug development [57, 43, 12].”
BackgroundUse of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
Shea, M. B., Roberts, S. A., Walrath, J. C., Allen, J. D., & Sigal, E. V. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0316 · Cited by 29
Baumann, M., Baxendale, I. R., Hornung, C., Ley, S. V., Rojo, M. V., & Roper, K. A. (2014) · Molecules · doi:10.3390/molecules19079736 · Cited by 29
“Even though the search for new promising lead compounds continues to be a constant within pharmaceutical and agrochemical research environments, the last 15 years have witnessed a true step change in how such structures are prepared and evaluated [7–9].”
BackgroundHosomi, K., Fujimoto, M., Ushio, K., Mao, L., Kato, J., & Takada, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204648 · Cited by 33
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Wuelfing, W. P., Marrouni, A. E., Lipert, M. P., Daublain, P., Kesisoglou, F., Converso, A., & Templeton, A. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01687 · Cited by 29
Maria, J. P. S., Wang, Y., & Camargo, L. M. (2023) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2023.1121591 · Cited by 29
“…on by adopted technologies, our industry follows “ Eroom ’ s Law ” , an observed exponential decay in FDA new drug approvals per billion dollars of R&D investment (Scannell, et al., 2012), highlighting a key expectation-reward gap between technological investments and payout in therapeutics.”
BackgroundMetabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine
Khanra, S., Reddy, P. H., Giménez‐Palomo, A., Park, C. H. J., Panizzutti, B., McCallum, M., Arumugham, S. S., Shreekantiah, U., Debnath, M., Das, B., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02134-8 · Cited by 29
Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study
Krouse, A. J., Gray, L. A., Macdonald, T. L., & McCray, J. E. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.29014.ajkdrrr · Cited by 29
Computational allosteric ligand binding site identification on Ras proteins
McCarthy, M. J., Prakash, P., & Gorfe, A. A. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv100 · Cited by 31
“Drug discovery, however, is a very complex and expensive process that takes years and costs billions of dollars [60].”
BackgroundUsing Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors
Jerome, R. N., Pulley, J. M., Roden, D. M., Shirey-Rice, J. K., Bastarache, L. A., Bernard, G. R., Ekstrom, L. B., Lancaster, W. J., & Denny, J. C. (2017) · Drug Safety · doi:10.1007/s40264-017-0616-0 · Cited by 29
“Given it is widely accepted that many existing in vitro and preclinical animal models are poor predictors of human biology [19], the method described here provides an alternative approach to accurate prediction of the physiologic effects of new therapies in humans.”
Marshall, L. J., Triunfol, M., & Seidle, T. (2020) · Animals · doi:10.3390/ani10101923 · Cited by 29
Recommendations toward a human pathway-based approach to disease research
Marshall, L. J., Austin, C. P., Casey, W., Fitzpatrick, S. C., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.038 · Cited by 28
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
“Despite novel advances in HTS, improvements in the reproducibility of in vivo models and increased understanding of the mechanism of disease, the number of approved novel drugs is much lower than expected [480].”
Kenakin, T., Bylund, D. B., Toews, M. L., Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.024 · Cited by 28
Vegvari, C., Hadjichrysanthou, C., Cauët, E., Lawrence, E., Cori, A., de Wolf, F., & Anderson, R. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158237 · Cited by 28
“A major part of this cost increase is due to losses incurred on drug candidates that fail during clinical development[2].”
BackgroundDrug repurposing with network reinforcement
Nam, Y., Kim, M.-J., Chang, H., & Shin, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2858-6 · Cited by 28
Cleary, E. G., Jackson, M. J., & Ledley, F. D. (2020) · doi:10.36687/inetwp133 · Cited by 34
Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective
Smolková, B., Frtús, A., Uzhytchak, M., Lunová, M., Kubinová, Š., Dejneka, A., & Lunov, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176226 · Cited by 31
“Overall, in recent years, pharmaceutical drug research and development show declining output in terms of the number of new drugs [166].”
BackgroundAlvaBuilder: A Software for De Novo Molecular Design
Mauri, A., & Bertola, M. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00610 · Cited by 30
“This phenomenon has been described by Eroom’s law, 4 which is essentially Moore’s law spelled backward.”
MethodNandal, S., & Burt, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020448 · Cited by 28
Fibrosis in tissue engineering and regenerative medicine: treat or trigger?
Fernández‐Colino, A., Iop, L., Ferreira, M. S. V., & Mela, P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.007 · Cited by 30
The Anticancer Drug Discovery Potential of Marine Invertebrates from Russian Pacific
Katanaev, V. L., Falco, S. D., & Khotimchenko, Y. S. (2019) · Marine Drugs · doi:10.3390/md17080474 · Cited by 28
Clinical Research and Regulatory Affairs: Skills and Tools in Pharmacy Education
Herdeiro, M. T., Gouveia, N., & Roque, F. (2020) · Advances in medical education, research, and ethics (AMERE) book series · doi:10.4018/978-1-7998-4486-0.ch008 · Cited by 28
Costantino, L., & Barlocco, D. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.193 · Cited by 28
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
Kim, H. R., Taslakjian, B., Kim, S., Tirrell, M., & Guler, M. O. (2024) · ChemBioChem · doi:10.1002/cbic.202300831 · Cited by 30
Otto, B., Schüßler, E., Sydow, J., & Vogelgsang, L. (2024) · Organization Science · doi:10.1287/orsc.2020.14743 · Cited by 28
BalestraWeb: efficient online evaluation of drug–target interactions
Çobanoğlu, M. C., Oltvai, Z. N., Taylor, D. L., & Bahar, İ. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu599 · Cited by 32
“Summary: BalestraWeb is an online server that allows users to in- stantly make predictions about the potential occurrence of interactions between any given drug–target pair, or predict the most likely inter- action partners of any drug or target listed in the DrugBank.”
BackgroundGuiding Conventional Protein–Ligand Docking Software with Convolutional Neural Networks
Jiang, H., Fan, M., Wang, J., Sarma, A., Mohanty, S., Dokholyan, N. V., Mahdavi, M., & Kandemir, M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00542 · Cited by 27
Bizzarri, M., Fedeli, V., Monti, N., Cucina, A., Jalouli, M., Alwasel, S. H., & Harrath, A. H. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00254-1 · Cited by 31
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.